Audited Financial Results (Standalone & Consolidated) of the Company for the half year and financial year ended 31.03.2026, along with the Audit Reports thereon.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 3.2 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mahamaya Lifesciences reported consolidated revenue of ₹32,887 Lakhs for FY26, up 24.5% from ₹26,415 Lakhs in FY25, driven by its agrochemicals business. Profit after tax grew 29% to ₹1,652 Lakhs from ₹1,281 Lakhs. The company listed on BSE SME on 18th November 2025 through an IPO raising ₹64.28 Crores at ₹114 per share. Cash position improved significantly to ₹3,940 Lakhs from ₹399 Lakhs due to IPO proceeds. However, operating cash flow turned negative at ₹-2,958 Lakhs due to large increases in inventory (₹14,105 vs ₹10,021 Lakhs) and receivables. Short-term borrowings rose to ₹8,717 from ₹5,195 Lakhs. The auditor issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong topline and bottom-line growth in first results as a listed company is positive. However, investors should monitor the significant working capital stress and rising debt levels despite IPO inflows. The clean audit opinion removes governance concerns.